AR064421A1 - Sintesis mejorada para la preparacion del acido[r-(r*,r*)]-2-(4-fluorofenil)-beta-delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)carbonil]-1h-pirrol-1-heptanoico o una sal farmaceuticamente aceptable del mismo,asi como de intermediarios usados en el procedimiento. - Google Patents

Sintesis mejorada para la preparacion del acido[r-(r*,r*)]-2-(4-fluorofenil)-beta-delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)carbonil]-1h-pirrol-1-heptanoico o una sal farmaceuticamente aceptable del mismo,asi como de intermediarios usados en el procedimiento.

Info

Publication number
AR064421A1
AR064421A1 ARP070105698A ARP070105698A AR064421A1 AR 064421 A1 AR064421 A1 AR 064421A1 AR P070105698 A ARP070105698 A AR P070105698A AR P070105698 A ARP070105698 A AR P070105698A AR 064421 A1 AR064421 A1 AR 064421A1
Authority
AR
Argentina
Prior art keywords
formula
compound
pharmaceutically acceptable
acceptable salt
defined above
Prior art date
Application number
ARP070105698A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR064421A1 publication Critical patent/AR064421A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrrole Compounds (AREA)
ARP070105698A 2006-12-19 2007-12-18 Sintesis mejorada para la preparacion del acido[r-(r*,r*)]-2-(4-fluorofenil)-beta-delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)carbonil]-1h-pirrol-1-heptanoico o una sal farmaceuticamente aceptable del mismo,asi como de intermediarios usados en el procedimiento. AR064421A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87072806P 2006-12-19 2006-12-19

Publications (1)

Publication Number Publication Date
AR064421A1 true AR064421A1 (es) 2009-04-01

Family

ID=39142305

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105698A AR064421A1 (es) 2006-12-19 2007-12-18 Sintesis mejorada para la preparacion del acido[r-(r*,r*)]-2-(4-fluorofenil)-beta-delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)carbonil]-1h-pirrol-1-heptanoico o una sal farmaceuticamente aceptable del mismo,asi como de intermediarios usados en el procedimiento.

Country Status (4)

Country Link
JP (1) JP2008150376A (fr)
AR (1) AR064421A1 (fr)
TW (1) TW200848406A (fr)
WO (1) WO2008075165A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523404T3 (es) * 2007-08-03 2014-11-25 Pfizer Products Inc. Procedimiento de preparación de compuestos quirales
EP2560951B1 (fr) * 2010-04-19 2016-05-25 DSM Sinochem Pharmaceuticals Netherlands B.V. Production d'atorvastatine à faible teneur en impuretés éthers
US8816082B2 (en) 2010-05-28 2014-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US9290526B2 (en) 2010-05-28 2016-03-22 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
SI2616454T1 (sl) * 2010-09-16 2015-08-31 Dsm Sinochem Pharmaceuticals Netherlands B.V. Estri heksanojskih kislin, kot vmesne spojine za pripravo atorvastatina
FR2970178B1 (fr) * 2011-01-07 2014-06-20 Liliane Therese Jacquot Promedicaments pour une delivrance specifique au niveau du foie et une meilleure tolerance

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis

Also Published As

Publication number Publication date
WO2008075165A1 (fr) 2008-06-26
TW200848406A (en) 2008-12-16
JP2008150376A (ja) 2008-07-03

Similar Documents

Publication Publication Date Title
AR064421A1 (es) Sintesis mejorada para la preparacion del acido[r-(r*,r*)]-2-(4-fluorofenil)-beta-delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)carbonil]-1h-pirrol-1-heptanoico o una sal farmaceuticamente aceptable del mismo,asi como de intermediarios usados en el procedimiento.
FI94339B (fi) Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CZ285554B6 (cs) Způsob výroby trans-6-[2-(substituovaný pyrrol-1-yl)alkyl]-pyran-2-onu
TR200402543T4 (tr) Amorf atorvastatinin hazırlanması işlemi.
AR063710A1 (es) Proceso para la preparacion de acido 6-(3-cloro-2-fluorbencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolon-3-carboxilico como inhibidores de integrasa del hiv e intermediarios de sintesis del mismo y composiciones que lo comprenden.
CA2436122A1 (fr) Procede de synthese de la forme v de l'atorvastatine et de phenylboronates utilises en tant que composes intermediaires
BRPI0411268A (pt) processo para a preparação de um composto 3-aril butil-amina substituìdo
CY1115696T1 (el) Μεθοδος για την παρασκευη υποκατεστημενου με διαρυλιο 4-αμινο-βουτυρικου οξεος ή παραγωγων του και η χρηση τους για την παρασκευη αναστολεων νερ
UY24985A1 (es) Formas cristalinas hidratadas de atorvastatina forma i
CL2009000089A1 (es) Procesos de preparacion de un derivado del acido y-amino-o-bifenil-x-metil-pentanoico;compuestos intermediarios y su proceso de preparacion; uso de los compuestos en la sintesis de compuestos inhibidores de nep, utiles en enfermedades cardiovasculares, tales como hipertension, insuficiencia cardiaca congestiva, entre otras.
AR055779A1 (es) Proceso de preparacion de azoxistrobina y composicion que contiene al compuesto
EA200900817A1 (ru) Способ получения фторметилзамещённых гетероциклических соединений
BRPI0612475B8 (pt) métodos para a preparação de um composto
BRPI0510713A (pt) formas de sal de ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-diidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)ca rbonil]-1h-pirrol-1- heptanóico
ATE441627T1 (de) Verfahren zur herstellung von valsartan
AR055975A1 (es) Procedimiento para producir atorvastatina,sus sales farmaceuticamente aceptables y sus productos intermedios
ATE467615T1 (de) N-substituierte 3,4-alkylendioxypyrrole, estersubstituierte dihydroxypyrrole und verfahren zur synthese dieser pyrrole
PE20091948A1 (es) Pirrolidin amidas sustituidas como moduladores del receptor histamina h3
US7615647B2 (en) Process for producing atorvastatin hemicalcium
NO20060716L (no) Krystallinske former av `R-(Rx,)-2(4-fluorfenyl)-beta, delta-dihydroksy-5-(1metyletyl)-3-fenyl-4-`(fenylamino) karbonyl-1H-pyrrol-1-hetpansyre
EA200800633A1 (ru) Способ получения производных сартана и промежуточных соединений, пригодных для этого способа
WO2009007856A3 (fr) Nouveau polymorphe d'atorvastatine calcium et son utilisation pour la préparation d'atorvastatine calcium amorphe
ATE411314T1 (de) Verfahren zur gewinnung der pharmazeutisch aktiven verbindung dolasetron, synthese- zwischenprodukte davon und verfahren zu deren gewinnung
WO2011131601A1 (fr) Production d'atorvastatine à faible teneur en impuretés lactones
Lee et al. An efficient method for the large-scale synthesis of atorvastatin calcium

Legal Events

Date Code Title Description
FA Abandonment or withdrawal